NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 3.56 against a street estimate of 5.80 — a miss of 38.6%.
with an average price target of ₹1,088.50.
| Document | Date |
|---|---|
| Quarterly results · Q1 FY27 JUBILANT PHARMOVA LIMITED – Q1 FY2026-27 RESULTS SUMMARY HEADLINE NUMBERS • Consolidated Revenue (Q1 FY2026-27): ₹22,294 million, down 2.7% from ₹22 | 2026-08-10 |
| Annual report FY2026 JUBILANT PHARMOVA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Dividend declared: ₹5 per equity share of face value ₹1 each for FY 2025-26 • Divide | 2026-08-01 |
| Q4 FY26 earnings call JUBILANT PHARMOVA LIMITED - Q4 & FY2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY2026 Revenue: Rs. 2,290 Crores (19% YoY growth) • Q4 FY2026 EBITDA: | 2026-05-27 |
| Quarterly results · Q4 FY26 JUBILANT PHARMOVA LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Total Revenue (Year ended March 31, 2026): ₹83,456 million, up from ₹72,913 million | 2026-05-22 |
| Quarterly results · Q3 FY26 JUBILANT PHARMOVA LIMITED – FINANCIAL RESULTS SUMMARY Q3 FY2026 (9 Months Ended 31 December 2025) --- HEADLINE NUMBERS CONSOLIDATED (GROUP) RESULTS | 2026-02-06 |
| Quarterly results · Q2 FY26 JUBILANT PHARMOVA LIMITED – H1 FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 FY2026 Revenue from Operations: ₹663 million (vs ₹595 million in Q2 FY | 2025-10-31 |
| Annual report FY2025 JUBILANT PHARMOVA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Dividend: ₹5 per equity share of face value ₹1 each for FY 2024-25 proposed (pending | 2025-08-05 |
| Investor presentation · Q1 FY26 JUBILANT PHARMOVA LIMITED – Q1 FY26 RESULTS SUMMARY HEADLINE NUMBERS • Revenue from operations: Rs. 1,901 Cr. in Q1'FY26, up 10% YoY (vs Rs. 1,732 C | 2025-07-29 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹5 / share ex-date Jul 24, 2026 | 2026-07-24 |
| Announcement | Date |
|---|---|
| USFDA approval for Line 3 contract manufacturing facility in Spokane Jubilant Pharmova Limited announced that the US FDA has approved commercial batch manufacturing on Line 3 of its Jubilant HollisterStier LLC contract manufacturing facility in Spokane, USA. | 2026-08-23 |
| Acquisition of another business announced Jubilant Pharmova Limited has informed the Exchange about Acquisition | 2025-12-30 |
| New high-speed isolator production line launched at US facility Jubilant Pharmova Limited announced the launch of a new high-speed isolator-based manufacturing line at its Spokane facility in the US through its wholly-owned subsidiary Jubilant HollisterS | 2025-10-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Jubilant Pharmova Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.